280118-23-2

Basic information

• Product Name: BMS-740808
• Synonyms: BMS-740808;1-(3-Amino-1,2-benz[d]isoxazol-5-yl)-3-trifluoromethyl-6-[4-[2-[[(3R)-3-hydroxy-1-pyrrolidinyl]methyl]phenyl]phenyl]-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one;1-(3-amino-1,2-benzoxazol-5-yl)-6-[4-[2-[[(3R)-3-hydroxypyrrolidin-1-yl]methyl]phenyl]phenyl]-3-(trifluoromethyl)-4,5-dihydropyrazolo[3,4-c]pyridin-7-one
• CAS NO: 280118-23-2
• Molecular Formula: C31H27F3N6O3
• Molecular Weight: 588.5796896
• Mol File: 280118-23-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 810.3 °C at 760 mmHg
• Flash Point: 443.9 °C
• Appearance: /
• Density: 1.52
• PKA: 14.79±0.20(Predicted)
• CAS DataBase Reference: BMS-740808(CAS DataBase Reference)
• NIST Chemistry Reference: BMS-740808(280118-23-2)
• EPA Substance Registry System: BMS-740808(280118-23-2)

Safety Data

• Hazardous Substances Data: 280118-23-2(Hazardous Substances Data)

Usage

General Description

BMS-740808 is a potent and selective antagonist of the histamine H3 receptor, which is primarily expressed in the central nervous system. BMS-740808 has been studied for its potential use in the treatment of various neurological and psychiatric disorders, including schizophrenia, attention deficit hyperactivity disorder (ADHD), and cognitive deficits associated with aging. BMS-740808 has shown promising results in preclinical studies, demonstrating its ability to improve cognitive function and attention in animal models. Additionally, it has been suggested that BMS-740808 may have potential as a treatment for obesity, as the histamine H3 receptor is involved in the regulation of appetite and metabolism. Further research is needed to fully explore the therapeutic potential of BMS-740808 in these various conditions.

Upstream product

• 546-88-3 acetylhydroxamic acid 
• 161886-21-1 2-fluoro-5-hydrazinobenzonitrile 
• 540-37-4 p-aminoiodobenzene 
• 53312-81-5 3-cyano-4-fluoroaniline 
• 4509-90-4 5-bromovaleroyl chloride 
• 543745-12-6 1-(3-Cyano-4-fluoro)phenyl-3-trifluoromethyl-6-[4-(2-formyl)phenyl]phenyl-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one 
• 543745-11-5 1-(3-cyano-4-fluoro)phenyl-3-trifluoromethyl-6-(4-iodo)phenyl-1,4,5,6-tetrahydro-7H-pyrazolo[3,4-c]pyridin-7-one 
• 385425-14-9 1-(4-iodophenyl)-4-(2,2,2-trifluoroacetyl)-piperidine-2,3-dione 
• 473927-69-4 1-(4-iodo-phenyl)-3-morpholin-4-yl-5,6-dihydro-1H-pyridin-2-one 
• 545445-10-1 3,3-dichloro-1-(4-iodophenyl)-piperidin-2-one 
• 385425-15-0 1-(2-oxopiperidin-1-yl)-4-iodobenzene 

Relevant articles and documents

1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa

Attempts to further optimize the pyrazole factor Xa inhibitors centered on masking the aryl aniline P4 moiety. Scaffold optimization resulted in the identification of a novel bicyclic pyrazolo-pyridinone scaffold which retained fXa potency. The novel bicyclic scaffold preserved all binding interactions observed with the monocyclic counterpart and importantly the carboxamido moiety was integrated within the scaffold making it less susceptible to hydrolysis. These efforts led to the identification of 1-[3-aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one 6f (BMS-740808), a highly potent (fXa Ki = 30 pM) with a rapid onset of inhibition (2.7 × 107 M-1 s-1) in vitro, selective (>1000-fold over other proteases), efficacious in the AVShunt thrombosis model, and orally bioavailable inhibitor of blood coagulation factor Xa.